Tumor markers in response monitoring and prognosis of non-small cell lung cancer: Preliminary report

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 631-634

  Vinolas N ^a   Molina, R ^a   Galan M C ^a   Casas, F ^a   Callejas, M A ^a   Filella, X ^a   Grau, J J ^a   Ballesta, A M ^a   Estape, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Disease monitoring; Lung cancer; Prognosis; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19; ETOPOSIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OTOTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0031924565     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jadvapour M, McIntire R, Waldama TA, et al: The role of radioimmunoassay of serum alphafetoprotein and human chorionic gonadotropin in the intensive chemotherapy and surgery of metastatic testicular tumors. J Urol 119: 759-762, 1978.
2. Martin EW, Cooperman M, Carey LC, Minton JP: Sixty second-look procedures indicated primiraly by serial carcinoembryonic antigen. J Surg Res 28: 389-394, 1980.
3. Canney PA, Moore M, Wilkinson PM, James RD: Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 50: 765-769, 1984.
4. Filella X, Molina R, Ballesta AM, et al: Value of PSA (Prostate-specific antigen) in the detection of prostate cancer in patients with urological sympthoms. Results of a multicentre study. Eur J Cancer 32: 1125-1128, 1996.
5. Graze K, Spiler IJ, Tashjiar AH, et al: Natural history of familiar medullary thyroid carcinoma. Effect of a program for early diagnosis. N Engl J Med 42: 1419-1421, 1978.
6. Molina R, Zanon G, Filella X, et al: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Br Cancer Res Treat 36: 41-48, 1995.
7. Molina R, Torres MD, Moragas M, et al: Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Tumor Biol 17: 81-89, 1996.
8. Ballesta AM, Calvet X, Filella X, et al: Alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. J Nucl Med Allied Sci 3: 39-41, 1989.
9. Concannon JP, Dalbow MH, Liebler GA, et al: The CEA assay in bronchogenic carcinoma. Cancer 34: 184-192, 1974.
10. Santabarbara P, Molina R, Estape J, Ballesta AM: Phosphohexose isomerase and carcinoembryonic antigen in the sera of patients with primary lung cancer. Int J Biol Markers 2: 113-122, 1988.
11. Sculier JP, Feld R, Evans FA, et al: Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. J Clin Oncol 3: 1349-1354, 1985.
12. Ariyoshi Y, Kato K, Ishiguro Y, Ota K, Suchi T: Evaluation of serum neuron-specific enolase as a tumor marker for carcinoma of the lung. Gann 74: 219-225, 1983.
13. Cooper EH, Splinter TAW, Brown DA, Muers MF, Peake MD, Pearson SL: Evaluation of a radioimmunoassay for neuron-specific enolase in small cell lung cancer. Br J Cancer 52: 333-338, 1985.
14. Molina R, Santabarbara P, Filella X, Mengual P, Ballesta AM: Preliminary study on CA 125 and CA 19.9 in primary lung cancer. Relationship with histologycal subtype of lung carcinoma. Int J Biol Markers 4: 215-220, 1990.
15. Mizushima Y, Hirata H, Izumi S, et al: Clinical significance of the number of positive markers in assisting the diagnosis of lung cancer with multiple tumor marker assay. Oncology 47: 43-48, 1990.
16. Molina R, Filella X, Torres MD, et al: SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 136: 251-254, 1990.
17. Upham J, Campbell B: Utility of squamous cell carcinoma antigen (SCC ag) as a tumor marker in pulmonary malignancy. Respiratory Medicine 86: 201-203, 1992.
18. Broers JLV, Ramekers FCS, Klein Rot M, et al: Cytokeratins in different types of human lung cancer as monitored by cahinspecific monoclonal antibodies. Cancer Res 48: 3221-3229, 1988.
19. Molina R, Agusti C, Filella X, Jo J, Joseph J, Gimenez N, Ballesta AM: Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumor Biol 15: 318-325, 1994.
20. Stieber P, Hasholzner U, Bodenmuller H, et al: CYFRA 21-1 a new marker in lung cancer. Cancer 72: 707-713, 1993.
21. Eberth W, Leichtweis B, Schapoler B, Muley Th: The new tumor marker CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer. Tumor Diag Therapie 14: 91-99, 1993.
22. Molina R, Agusti C, Mahe M, et al: CYFRA 21.1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 9: 96-101, 1994.
23. Vincent RG, Chu TM, Fergen TB, Ostrander M: Carcinoembryonic antigen in 228 patients with carcinoma of the lung. Cancer 36: 2069-2076, 1975.
24. Muller T, Marshall RJ, Cooper EH, Watson DA, Walker DA, Mearns AJ: The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis. Eur J cancer Clin Oncol 21: 1461-1466, 1985.
25. Niklinski J, Furman M, Laudanski J, Kozlowski M: Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1: 401-406, 1992.
26. Pujol JL, Grenier J, Daures JP, Daver A, PUiol H, Michel FB: Serum fragment of cytocheratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61-66, 1993.
27. Dent PB, McCulloch PB, Wesley-James O, MacLaren R, Muirhead W, Dunnett CW: Measurement of Carcinoembryonic antigen in patients with bronchogenic carcinoma. Cancer 42: 1484-1491, 1978.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
29. Kaplan GL, Meier P: Nonparametric estimations from incomplete observations. Am Statist Ass J 53: 457-481, 1958.
30. Niklinski J, Furman M, Rappellino M, et al: CYFRA 21.1 determination in patients with non-small cell lung cancer: clinical utility for the detection of recurrence. J Cardiovasc Surg 36: 501-504, 1995.
31. Kibbellar RE, Moolenaar KEC, Michalides RJAM, et al: Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 27: 431-435, 1991.
32. Berendsen HH, de Leij L, Poppema S et al: Clinical characterization of non-small-cell-lung cancer. Tumors showing neuroendocrine differentiation features. J Clin Oncol 7: 1614-1620, 1989.
33. Wieskopf B, Demangeat C, Purohit A et al: Cyfra 21.1 as biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity and prognostic role. Chest 108: 163-169, 1995.
34. Buccheri G, Ferrigno D and Vola F: Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung cancer 10: 21-33, 1993.
35. Van der Gaast A, Kok TC, Kho GS, Blijenberg BG, Splinter TAW: Disease monitoring by tumour markers Cyfra 21.1 and TPA in patients with non-small cell lung cancer. Eur J Cancer 31A: 1790-1793, 1995.
36. Graziano SL, Mazid R, Newman N et al: The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol 7: 1398-1406, 1989.
37. Dienemann H, Stieber P, Zimmermann A, Hoffmann H, Muller C, Banauch D: Tumor-marker Cyfra 21.1 in non-small-cell lung cancer (NSCLC): role for detection of recurrence. Lung Cancer 11 (suppl 1): 46, 1994.